Green Goo Announces NFL Linebacker Shaq Thompson as Brand Ambassador
Plant-based body care brand launches Rub It In campaign and ticket giveaway to football's biggest game in Glendale, AZ on February 12, 2023 LYONS, Colo., Nov. 16, 2022 /PRNewswire/ -- The plant-based Sierra Sage Herbs body care brand, Green Goo, is proud to announce Shaq Thompson, National Football League (NFL) linebacker and...
Mintal Tracker Wins Highest Honor From Prestigious 2022 Fall Digital Health Awards
The award-winning app uses AI to monitor and help users achieve healthier sleep SUNNYVALE, Calif., Nov. 29, 2022 /PRNewswire/ -- Mintal Tracker, a sleep tracking app driven by artificial intelligence (AI) technology that offers a scientific approach to healthier sleep, received a 2022 Gold Award in the Mobile Application category of the Fall session of the 24th annual...
New CRISPR/Cas9 license agreement for ERS Genomics and Cosmo Bio
Return to the index page SQL ERROR Can't connect to MySQL server on '192.168.120.250' (111) An sql error occurred while fetching this page. Please contact an administrator if this problem persists. Powered by PRN Asia 2011 PRN Asia
WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers
WuXi Biologics will provide an exclusive license to GSK for one preclinical bi-specific T cell engaging (TCE) antibody and the option of three additional bi-/multi-specific TCE antibodies developed using WuXi Biologics' proprietary technology platforms WuXi Biologics will receive an upfront payment of $40 million and tiered royalties on net sales SHANGHAI, Jan. 5, 2023 /PRNewswire/ -- WuXi...
Medtech Innovator magAssist Inc. Gains Recognition for Its Innovation in the Cardiovascular Field at 2022 Critical Heart Disease Congress-International Society for Mechanical Circulatory Support Parallel Forum
SUZHOU, China, Jan. 16, 2023 /PRNewswire/ -- magAssist Inc. ("magAssist"), a leading global developer of extracorporeal life support devices, attended the 2022 Critical Heart Disease Congress - International Society for Mechanical Circulatory Support Parallel Forum, where the firm shared the latest research results and technologies for the treatment of critical heart diseases with fellow cardiovascular researchers and experts, demonstrating...
Everise Repositions Branding to Cement Evolution as End-to-End Customer Service Player
Launches new corporate slogan "Champions of customer happiness" and brand video PLANTATION, Fla., Jan. 18, 2023 /PRNewswire/ -- Leading customer service company Everise announced today the launch of its new brand repositioning, which includes a refreshed visual identity and the new brand tagline, "Champions of Customer Happiness". As of January 2023,...
Picarro and LESNI Partner to Deliver Comprehensive Ethylene Oxide Monitoring Solutions to Sterilization Facilities Worldwide
Combination of LESNI's abatement systems expertise and Picarro's advanced monitoring and data analytics technology will enable improvements in industrial emissions control SANTA CLARA, Calif., March 23, 2023 /PRNewswire/ -- Picarro, Inc. and LESNI A/S today announced a strategic partnership aimed at delivering industry-leading Ethylene Oxide (EtO or EO) monitoring solutions to medical device and contract sterilization facilities around the...
Viva Biotech Attended SAPA-China
HONG KONG, April 13, 2023 /PRNewswire/ -- 6th-7th April, the "2022 SAPA-China Annual Conference - Opportunities and Challenges for the Development of China's Biopharmaceutical Industry" hosted by The Sino-American Pharmaceutical Professionals Association (SAPA) was held in Chengdu, Sichuan. Viva Biotech was invited to participate in this annual conference, and Dr. Jianhua Cai, Senior Vice President of Viva Biotech, and...
Biosyngen announces FDA IND approval of its second product for EBV-positive lymphoma
GUANGZHOU, China, April 18, 2023 /PRNewswire/ -- April 15, 2023, Biosyngen Pte Ltd (hereinafter as "Biosyngen") announced that the Company received IND approval for its second product in the pipeline, a T-cell redirection therapy for the treatment of EBV-positive lymphoma. A week prior to this, the IND application of the same therapy...
LaNova Medicines Announces Global Exclusive License Agreement with AstraZeneca for LM-305, a Novel GPRC5D-Targeting Antibody Drug Conjugate
SHANGHAI, May 12, 2023 /PRNewswire/ -- LaNova Medicines Ltd. ("LaNova Medicines") announced today it has entered into an exclusive license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), for LM-305, a pre-clinical stage antibody drug conjugate (ADC) targeting G protein-coupled receptor, class C, group 5, member D (GPRC5D). Under the terms of the licensing agreement, AstraZeneca will be granted an exclusive global...
